ID   K562/G
AC   CVCL_C0HT
DR   Wikidata; Q112929938
RX   PubMed=21122350;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 02-05-24; Version: 5
//
RX   PubMed=21122350; DOI=10.3760/cma.j.issn.0253-2727.2010.06.003;
RA   Jia H.-Y., Wu X.-M., Wang Z.-Y., Deng X.-Y., Lin Z., Feng G.-L.,
RA   Huang W.-L.;
RT   "Effect of ZD6474 on the proliferation of imatinib-resistant K562
RT   cells.";
RL   Zhonghua Xue Ye Xue Za Zhi 31:371-375(2010).
//